{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-002711","form_type":"8-K","ticker":"DRMA","cik":"0001853816","company_name":"Dermata Therapeutics, Inc.","filed_at":"2023-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.170355+00:00","generated_at":"2026-06-18T04:54:03.818925+00:00","sec_items":["3.03","5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Dermata Therapeutics files 1-for-16 reverse stock split, effective March 14, 2023","bullets":["Board approved a 1-for-16 reverse split of common stock on March 8; filed with Delaware on March 13.","Split effective 12:01 a.m. ET on March 14, 2023; Nasdaq trading begins on split-adjusted basis same day.","No fractional shares issued; stockholders receive cash in lieu of any fractional interest.","CUSIP number for common stock changes to 249845306.","All outstanding options and warrants adjusted proportionally; authorized shares unchanged."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-002711","json":"https://secwatch.observer/filing/0001654954-23-002711.json","markdown":"https://secwatch.observer/filing/0001654954-23-002711.md","text":"https://secwatch.observer/filing/0001654954-23-002711.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1853816/000165495423002711/0001654954-23-002711-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1853816/000165495423002711/drma_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T04:54:03.818925+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6383bdfb62169e0c075896535381b62db0d2207c","claim":"Dermata Therapeutics, Inc.: Effect a 1-for-16 reverse stock split via Certificate of Amendment to Amended and Restated Certificate of Incorporation (effective 2023-03-14).","evidence_excerpt":"On March 13, 2023, Dermata Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware (the “Certificate of Amendment”), which will effect, at 12:01 a.m. Eastern Time, on March 14, 2023, a 1-for-16 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding shares of common stock, par value $0.0001 per share (the “Common Stock”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495423002711/0001654954-23-002711-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-03-14"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}